Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2014, Article ID 818530, 7 pages
http://dx.doi.org/10.1155/2014/818530
Review Article

New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy

1Department of Nephrology, Nanjing Children’s Hospital, Nanjing Medical University, Nanjing 210008, China
2Institute of Pediatrics, Nanjing Medical University, Nanjing, China
3Key Pediatric Laboratory of Nanjing City, Nanjing 210008, China
4Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA 19104, USA
5Department of Internal Medicine, University of Utah, Salt Lake City, UT 84132, USA

Received 18 November 2013; Accepted 16 December 2013; Published 29 January 2014

Academic Editor: Lihong Chen

Copyright © 2014 Zhanjun Jia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. M. Evans, G. D. Barish, and Y.-X. Wang, “PPARs and the complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp. 355–361, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. G. D. Barish, V. A. Narkar, and R. M. Evans, “PPARδ: a dagger in the heart of the metabolic syndrome,” The Journal of Clinical Investigation, vol. 116, no. 3, pp. 590–597, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Poulsen, M. Siersbæk, and S. Mandrup, “PPARs: fatty acid sensors controlling metabolism,” Seminars in Cell & Developmental Biology, vol. 23, no. 6, pp. 631–639, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Tontonoz and B. M. Spiegelman, “Fat and beyond: the diverse biology of PPARγ,” Annual Review of Biochemistry, vol. 77, pp. 289–312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. P. A. Sarafidis, P. C. Stafylas, P. I. Georgianos, A. N. Saratzis, and A. N. Lasaridis, “Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis,” American Journal of Kidney Diseases, vol. 55, no. 5, pp. 835–847, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. H.-C. Yang, L.-J. Ma, J. Ma, and A. B. Fogo, “Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis,” Kidney International, vol. 69, no. 10, pp. 1756–1764, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. I. Miceli, D. Burt, E. Tarabra, G. Camussi, P. C. Perin, and G. Gruden, “Stretch reduces nephrin expression via an angiotensin II-AT1-dependent mechanism in human podocytes: effect of rosiglitazone,” American Journal of Physiology, vol. 298, no. 2, pp. F381–F390, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Yang, Y. Zhou, and Y. Guan, “PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases,” Current Opinion in Nephrology and Hypertension, vol. 21, no. 1, pp. 97–105, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Lepenies, M. Hewison, P. M. Stewart, and M. Quinkler, “Renal PPARγ mRNA expression increases with impairment of renal function in patients with chronic kidney disease,” Nephrology, vol. 15, no. 7, pp. 683–691, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Sugawara, A. Uruno, M. Kudo, K. Matsuda, C. W. Yang, and S. Ito, “Effects of PPARγ on hypertension, atherosclerosis, and chronic kidney disease,” Endocrine Journal, vol. 57, no. 10, pp. 847–852, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. A. B. Fogo, “PPARγ and chronic kidney disease,” Pediatric Nephrology, vol. 26, no. 3, pp. 347–351, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Ahmadian, J. M. Suh, N. Hah et al., “PPARγ signaling and metabolism: the good, the bad and the future,” Nature Medicine, vol. 99, no. 5, pp. 557–566, 2013. View at Publisher · View at Google Scholar
  13. J. Kung and R. R. Henry, “Thiazolidinedione safety,” Expert Opinion on Drug Safety, vol. 11, no. 4, pp. 565–579, 2012. View at Publisher · View at Google Scholar
  14. S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” The New England Journal of Medicine, vol. 356, no. 24, pp. 2457–2471, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Zhang, L. Villacorta, L. Chang et al., “Nitro-oleic acid inhibits angiotensin II-induced hypertension,” Circulation Research, vol. 107, no. 4, pp. 540–548, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Wang, H. Liu, Z. Jia et al., “Nitro-oleic acid protects against endotoxin-induced endotoxemia and multiorgan injury in mice,” American Journal of Physiology, vol. 298, no. 3, pp. F754–F762, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Liu, Z. Jia, S. Liu et al., “Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice,” American Journal of Physiology, vol. 305, no. 11, pp. F1555–F1562, 2013. View at Publisher · View at Google Scholar
  18. H. Liu, Z. Jia, S. Soodvilai et al., “Nitro-oleic acid protects the mouse kidney from ischemia and reperfusion injury,” American Journal of Physiology, vol. 295, no. 4, pp. F942–F949, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Wang, H. Liu, Z. Jia, G. Guan, and T. Yang, “Effects of endogenous PPAR agonist nitro-oleic acid on metabolic syndrome in obese zucker rats,” PPAR Research, vol. 2010, Article ID 601562, 7 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Kansanen, H.-K. Jyrkkänen, O. L. Volger et al., “Nrf2-dependent and -independent responses to nitro-fatty acids in human endothelial cells: identification of heat shock response as the major pathway activated by nitro-oleic acid,” The Journal of Biological Chemistry, vol. 284, no. 48, pp. 33233–33241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. L. S. Doshi, M. K. Brahma, U. A. Bahirat, A. V. Dixit, and K. V. S. Nemmani, “Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents,” Expert Opinion on Investigational Drugs, vol. 19, no. 4, pp. 489–512, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Centers for Disease, Prevention, “Incidence of end-stage renal disease among persons with diabetes—United States, 1990–2002,” Morbidity and Mortality Weekly Report, vol. 54, no. 43, pp. 1097–1100, 2005. View at Google Scholar
  23. E. J. Weil, K. V. Lemley, C. C. Mason et al., “Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy,” Kidney International, vol. 82, pp. 1010–1017, 2012. View at Publisher · View at Google Scholar
  24. K. Susztak, A. C. Raff, M. Schiffer, and E. P. Böttinger, “Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy,” Diabetes, vol. 55, no. 1, pp. 225–233, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Diez-Sampedro, O. Lenz, and A. Fornoni, “Podocytopathy in diabetes: a metabolic and endocrine disorder,” American Journal of Kidney Diseases, vol. 58, no. 4, pp. 637–646, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Guan and M. D. Breyer, “Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease,” Kidney International, vol. 60, no. 1, pp. 14–30, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Okada, J. Wada, K. Hida et al., “Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms,” Diabetes, vol. 55, no. 6, pp. 1666–1677, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. S. de Cosmo, S. Prudente, O. Lamacchia et al., “PPARγ2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies,” Nephrology Dialysis Transplantation, vol. 26, no. 12, pp. 4011–4016, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. J. Liang, J. H. Jian, C. Y. Chen, C. Y. Hsu, C. Y. Shih, and J. G. Leu, “L-165,041, troglitazone and their combination treatment to attenuate high glucose-induced receptor for advanced glycation end products (RAGE) expression,” European Journal of Pharmacology, vol. 715, no. 1–3, pp. 33–38, 2013. View at Publisher · View at Google Scholar
  30. Y. Qian, E. Feldman, S. Pennathur, M. Kretzler, and F. C. Brosius, “From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy,” Diabetes, vol. 57, no. 6, pp. 1439–1445, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Kanjanabuch, L.-J. Ma, J. Chen et al., “PPAR-γ agonist protects podocytes from injury,” Kidney International, vol. 71, no. 12, pp. 1232–1239, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Miglio, A. C. Rosa, L. Rattazzi et al., “The subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in decreasing podocyte injury,” British Journal of Pharmacology, vol. 162, no. 1, pp. 111–125, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. W. Wang, Y. Wang, J. Long et al., “Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells,” Cell Metabolism, vol. 15, no. 2, pp. 186–200, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Stieger, K. Worthmann, B. Teng et al., “Impact of high glucose and transforming growth factor-β on bioenergetic profiles in podocytes,” Metabolism, vol. 61, no. 8, pp. 1073–1086, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Zhu, S. Huang, Y. Yuan et al., “Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARγ,” The American Journal of Pathology, vol. 178, no. 5, pp. 2020–2031, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Shah and S. Mudaliar, “Pioglitazone: side effect and safety profile,” Expert Opinion on Drug Safety, vol. 9, no. 2, pp. 347–354, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Zhang, A. Zhang, D. E. Kohan, R. D. Nelson, F. J. Gonzalez, and T. Yang, “Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 26, pp. 9406–9411, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Guan, C. Hao, D. R. Cha et al., “Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption,” Nature Medicine, vol. 11, no. 8, pp. 861–866, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. K. B. Sotiropoulos, A. Clermont, Y. Yasuda et al., “Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARγ agonist's effects on edema and weight gain,” The FASEB Journal, vol. 20, no. 8, pp. 1203–1205, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Yang and S. Soodvilai, “Renal and vascular mechanisms of thiazolidinedione-induced fluid retention,” PPAR Research, vol. 2008, Article ID 943614, 8 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Robinson and D. J. Grieve, “Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease,” Pharmacology & Therapeutics, vol. 122, no. 3, pp. 246–263, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Aronoff, S. Rosenblatt, S. Braithwaite, J. W. Egan, A. L. Mathisen, and R. L. Schneider, “Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study,” Diabetes Care, vol. 23, no. 11, pp. 1605–1611, 2000. View at Publisher · View at Google Scholar · View at Scopus
  43. J. J. Nolan, N. P. Jones, R. Patwardhan, and L. F. Deacon, “Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus,” Diabetic Medicine, vol. 17, no. 4, pp. 287–294, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. M. K. Arora, K. Reddy, and P. Balakumar, “The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy,” European Journal of Pharmacology, vol. 636, no. 1–3, pp. 137–144, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. B. Cariou, B. Charbonnel, and B. Staels, “Thiazolidinediones and PPARγ agonists: time for a reassessment,” Trends in Endocrinology & Metabolism, vol. 23, no. 5, pp. 205–215, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Ueki, H. Kato, Y. Kobayashi et al., “Anti- and proinflammatory effects of 15-deoxy-Δ12,14-prostaglandin J2(15d-PGJ2) on human eosinophil functions,” International Archives of Allergy and Immunology, vol. 143, supplement 1, pp. 15–22, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. F. J. Schopfer, M. P. Cole, A. L. Groeger et al., “Covalent peroxisome proliferator-activated receptor γ adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions,” The Journal of Biological Chemistry, vol. 285, no. 16, pp. 12321–12333, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. M. C. Menon, P. Y. Chuang, and J. C. He, “Nitro-oleic acid is a novel anti-oxidative therapy for diabetic kidney disease,” American Journal of Physiology, vol. 305, pp. F1542–F1543, 2013. View at Publisher · View at Google Scholar
  49. T. Yew, S.-A. Toh, and J. S. Millar, “Selective peroxisome proliferator-activated receptor-γ modulation to reduce cardiovascular risk in patients with insulin resistance,” Recent Patents on Cardiovascular Drug Discovery, vol. 7, no. 1, pp. 33–41, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Agrawal, P. Jain, and S. N. Dikshit, “Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist,” Mini-Reviews in Medicinal Chemistry, vol. 12, no. 2, pp. 87–97, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Lamotte, P. Martres, N. Faucher et al., “Synthesis and biological activities of novel indole derivatives as potent and selective PPARγ modulators,” Bioorganic & Medicinal Chemistry Letters, vol. 20, no. 4, pp. 1399–1404, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. J. F. Dropinski, T. Akiyama, M. Einstein et al., “Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARγ partial agonists,” Bioorganic & Medicinal Chemistry Letters, vol. 15, no. 22, pp. 5035–5038, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Shah, D. J. Rader, and J. S. Millar, “The effect of PPAR-α agonism on apolipoprotein metabolism in humans,” Atherosclerosis, vol. 210, no. 1, pp. 35–40, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. P. Balakumar, S. Kadian, and N. Mahadevan, “Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?” Pharmacological Research, vol. 65, no. 4, pp. 430–436, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. D. R. Cha, X. Zhang, Y. Zhang et al., “Peroxisome proliferator-activated receptor α/γ dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice,” Diabetes, vol. 56, no. 8, pp. 2036–2045, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Liao, Z. Soltani, P. Ebenezer et al., “Tesaglitazar, a dual peroxisome proliferator- activated receptor agonist (PPARα/γ), improves metabolic abnormalities and reduces renal injury in obese zucker rats,” Nephron, vol. 114, no. 2, pp. e61–e68, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. E. Stitt-Cavanagh, L. MacLeod, and C. Kennedy, “The podocyte in diabetic kidney disease,” The Scientific World Journal, vol. 9, pp. 1127–1139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. H.-F. Cheng, C. J. Wang, G. W. Moeckel, M.-Z. Zhang, J. A. McKanna, and R. C. Harris, “Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension,” Kidney International, vol. 62, no. 3, pp. 929–939, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Makino, I. Tanaka, M. Mukoyama et al., “Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist,” Journal of the American Society of Nephrology, vol. 13, no. 7, pp. 1757–1765, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Mohamed, C. Jayakumar, and G. Ramesh, “Chronic administration of EP4-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6,” Laboratory Investigation, vol. 93, pp. 933–945, 2013. View at Publisher · View at Google Scholar
  61. H. Cheng, X. Fan, G. W. Moeckel, and R. C. Harris, “Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression,” Journal of the American Society of Nephrology, vol. 22, no. 7, pp. 1240–1251, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. E. M. Stitt-Cavanagh, W. H. Faour, K. Takami et al., “A maladaptive role for EP4 receptors in podocytes,” Journal of the American Society of Nephrology, vol. 21, no. 10, pp. 1678–1690, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Rios, H. Vargas-Robles, A. M. Gámez-Méndez, and B. Escalante, “Cyclooxygenase-2 and kidney failure,” Prostaglandins & Other Lipid Mediators, vol. 98, no. 3-4, pp. 86–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. Z. Jia, G. Liu, Y. Sun et al., “mPGES-1-derived PGE2 mediates dehydration natriuresis,” American Journal of Physiology, vol. 304, no. 2, pp. F214–F221, 2013. View at Publisher · View at Google Scholar
  65. Z. Jia, G. Liu, M. Downton, Z. Dong, A. Zhang, and T. Yang, “mPGES-1 deletion potentiates urine concentrating capability after water deprivation,” American Journal of Physiology, vol. 302, no. 8, pp. F1005–F1012, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. Z. Jia, T. Aoyagi, D. E. Kohan, and T. Yang, “mPGES-1 deletion impairs aldosterone escape and enhances sodium appetite,” American Journal of Physiology, vol. 299, no. 1, pp. F155–F166, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. Z. Jia, T. Aoyagi, and T. Yang, “mPGES-1 protects against DOCA-salt hypertension via inhibition of oxidative stress or stimulation of NO/cGMP,” Hypertension, vol. 55, no. 2, pp. 539–546, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. Z. Jia, H. Wang, and T. Yang, “Mice lacking mPGES-1 are resistant to lithium-induced polyuria,” American Journal of Physiology, vol. 297, no. 6, pp. F1689–F1696, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Soodvilai, Z. Jia, M.-H. Wang, Z. Dong, and T. Yang, “mPGES-1 deletion impairs diuretic response to acute water loading,” American Journal of Physiology, vol. 296, no. 5, pp. F1129–F1135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Soodvilai, Z. Jia, and T. Yang, “Hydrogen peroxide stimulates chloride secretion in primary inner medullary collecting duct cells via mPGES-1-derived PGE2,” American Journal of Physiology, vol. 293, no. 5, pp. F1571–F1576, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. Z. Jia, H. Wang, and T. Yang, “Microsomal prostaglandin e synthase 1 deletion retards renal disease progression but exacerbates anemia in mice with renal mass reduction,” Hypertension, vol. 59, no. 1, pp. 122–128, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. L. A. Jania, S. Chandrasekharan, M. G. Backlund et al., “Microsomal prostaglandin E synthase-2 is not essential for in vivo prostaglandin E2 biosynthesis,” Prostaglandins & Other Lipid Mediators, vol. 88, no. 3-4, pp. 73–81, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. A. K. Lovgren, M. Kovarova, and B. H. Koller, “cPGES/p23 is required for glucocorticoid receptor function and embryonic growth but not prostaglandin E2 synthesis,” Molecular and Cellular Biology, vol. 27, no. 12, pp. 4416–4430, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. Z. Jia, N. Wang, T. Aoyagi, H. Wang, H. Liu, and T. Yang, “Amelioration of cisplatin nephrotoxicity by genetic or pharmacologic blockade of prostaglandin synthesis,” Kidney International, vol. 79, no. 1, pp. 77–88, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. Sun, Z. Jia, G. Liu et al., “PPARγ agonist rosiglitazone suppresses renal mPGES-1/PGE2 pathway in db/db mice,” PPAR Research, vol. 2013, Article ID 612971, 9 pages, 2013. View at Publisher · View at Google Scholar